The alliance between British and Chinese companies is intended to speed up drug design
Cresset, software and contract research services for small molecule discovery, has signed a three-way strategic agreement to speed up drug design.
David Bardsley, Commercial Director of Cresset, visited the School of Pharmaceutical Sciences in Sun Yat-Sen University, Guangzhou (China).
There, he signed a cooperation agreement for drug design technology, developed within the Research Centre for Drug Discovery (RCDD).
This visit was in response to an invitation from Professor Jun Xu, RCDD. It was hosted by the Dean, Wenhao Hu and Huichang Bi, Vice Dean for International Development.
A further agreement was signed between Bardsley and DeKang Zhang, Chair of iPrecison Medicine Technology. In this agreement, Cresset will promote iPrecision software and technology globally.
This agreement follows the transfer of 10 drug design software patents from RCDD to iPrecision last year.
“This British-Chinese three-way agreement brings together expertise and innovation in development of technologies for computational molecule design,” said Bardsley. “I look forward to working with each organisation to establish global distribution channels.”